Hercules is a biopharmaceutical company developing an innovative, oral, non-toxic drug therapy for chronic treatment of patients with Triple Negative Breast Cancer, and other solid tumors.
We have demonstrated that blocking the Aryl hydrocarbon Receptor in solid tumors could:
Hercules have discovered novel anti-cancer drugs that block the Aryl Hydrocarbon receptor and is now testing these products in preparation for clinical trials.
Apart from breast cancer, Hercules’ approach has potential as treatment of other agressive solid tumors that highly express AhR, like glioblastoma, colorectal cancer and pancreatic cancer.
